B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Tom A. Barr(University of Glasgow), David Gray(London Postgraduate Medical and Dental Education), Simon Fillatreau(Hôpital Necker-Enfants Malades), Richard A. O’Connor(Queen's Medical Centre), Ping Shen(Humboldt-Universität zu Berlin), S. Lawrie(Montreal Neurological Institute and Hospital), Sheila Brown(University of Manchester), Amit Bar‐Or(University of Pennsylvania), Boli Fan(Montreal Neurological Institute and Hospital), Vicky Lampropoulou(National and Kapodistrian University of Athens), Stephen M. Anderton(Centre for Inflammation Research), Toralf Roch(Charité - Universitätsmedizin Berlin)
Cited by 651
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
|Nucleic Acids Research|2017|1.7k
B cells regulate autoimmunity by provision of IL-10
|Nature Immunology|2002|1.6k